Publication | Closed Access

Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China

MedicineImmunologyPathologyImmune Checkpoint InhibitorCancer TreatmentOncologyRadiation OncologyLung CancerIvonescimab Versus Pembrolizumab